Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report) was down 5.4% during trading on Tuesday . The company traded as low as $0.7144 and last traded at $0.7332. Approximately 170,162 shares were traded during trading, a decline of 99% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.7748.
Emerald Bioscience Stock Down 5.4%
The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.43. The stock’s 50-day moving average is $0.78. The firm has a market cap of $196.55 million, a price-to-earnings ratio of -9.17 and a beta of 0.43.
About Emerald Bioscience
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Featured Stories
- Five stocks we like better than Emerald Bioscience
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
